QC
AKBA icon

Quadrature Capital’s Akebia Therapeutics AKBA Stock Holding History

Quadrature Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124K Buy
89,261
+72,700
+439% +$99.9K ﹤0.01% 1195
2025
Q4 		$26.7K Buy
16,561
+6,293
+61% +$13.2K ﹤0.01% 1200
2025
Q3 		$28.1K Sell
10,268
-71,676
-87% -$238K ﹤0.01% 981
2025
Q2 		$297K Buy
81,944
+54,691
+201% +$150K 0.01% 693
2025
Q1 		$52.1K Buy
+27,253
New +$55.6K ﹤0.01% 973

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Quadrature Capital's AKBA Position: Q1 2026 in Review

Quadrature Capital increased its Akebia Therapeutics (AKBA) stake by 439% in Q1 2026, buying an estimated $99.9K and bringing the position to 89,261 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #1195.

Quadrature Capital first reported a position in AKBA in Q1 2025 and has held it in 5 quarters since. The position peaked at $297K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Quadrature Capital held 89,261 shares of Akebia Therapeutics worth $124K as of Q1 2026.
  • Quadrature Capital bought 72,700 Akebia Therapeutics shares in Q1 2026, an estimated $99.9K.
  • Akebia Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1195 holding.
  • Quadrature Capital first reported a position in Akebia Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Quadrature Capital's Akebia Therapeutics position peaked at $297K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.